Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tagraxofusp + azacitidine
- Development stage
- Unknown
- Lead developer
- Stemline Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Tagraxofusp + azacitidine is a combination therapy being evaluated as a maintenance treatment for patients with CD123-positive acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following allogeneic hematopoietic cell transplantation (HCT). Tagraxofusp is a first-in-class recombinant fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. It specifically targets the CD123 receptor (IL-3Rα), which is highly expressed on the surface of AML and MDS malignant cells, delivering the toxin to inhibit protein synthesis and induce cell death. Azacitidine is a hypomethylating agent that acts as a DNA methyltransferase inhibitor, promoting cell differentiation and exerting direct cytotoxic effects. This combination regimen is being investigated by the City of Hope Medical Center to improve outcomes and prevent disease relapse in high-risk post-transplant settings.
- Brand names
- ElzonrisVidaza
- Other names
- tagraxofusp-erzsCD123 Antibody Toxin CongregateCD-123 Antibody Toxin CongregateCD 123 Antibody Toxin Congregate
02
Targets
EEF2 (Eukaryotic elongation factor 2)IL3RA (Interleukin 3 Receptor)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on tagraxofusp + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tagraxofusp + azacitidine.